September 06, 2010

Eight 'Delhi superbug' docs in the dock

The notice has sought explanation why the doctors did not take mandatory permission from Indian Council of Medical Research (ICMR) to transfer the biomedical material outside the country. The eight doctors from Tamil Nadu, Haryana, West Bengal and Uttar Pradesh have been asked to respond within 15 days to the Drug Controller General of India (DCGI).

“It is a matter of concern if biomedical material can be transferred to foreign countries randomly. Like this, genetic mapping of our population can be done and exploited,” a senior health ministry official said, confirming that the DCGI sent the notice last week. Some see it as a move to armtwist and retaliate against the report and those who participated in the study. “There will obviously be political pressure to take action. But there is also a legitimate concern,” a senior industry executive said.

Dr Dharam Prakash, secretary general of the Indian Medical Association, said he cannot comment as he has not seen the notice. In a study published in The Lancet Infectious Diseases Journal on August 11, scientists said they had found a new gene — Delhi metallo-beta-lactamase (NDM-1) resistant to almost all antibiotics, including the most powerful class called carbapenems — in patients in South Asia and Britain. The patients in Britain had undergone treatment in the sub-continent, mainly in India.

The report warned NDM-1 could be a potential worldwide public health problem, but Indian health authorities and doctors ruled out such a possibility. The samples for the study were collected from hospital patients in Chennai and Haryana, and from patients referred to Britain’s national reference laboratory between 2007 and 2009.

Health experts, doctors and politicians alike have come out strongly against the report, particularly naming the bug after the Indian capital. This was seen by many as an attempt to malign the Indian healthcare sector, which is attracting foreign patients by providing healthcare services at cheap rates.

Such concerns are not new. Even in the pharmaceutical sector, Indian drugmakers have often refuted occasional reports of counterfeit drugs linked to India and have termed allegations that medicines made in India are of inferior quality, as an anti-tariff trade barrier to restrict Indian companies

Link: Original Article

1 comment:

†J said...

Hey Dear,
I'm sorry to be writing this here, but, cudn't find any other place.
Please cover the Jodhpur medical college incident, if you can.
For more details, kindly visit this:

Dr. Telly Jain



Related Posts with Thumbnails